Knight Therapeutics (TSX:GUD) Beneish M-Score: -2.70 (As of Jun. 25, 2026)


TSX:GUD Knight Therapeutics Inc TSX:GUD
73 GF Score
Price C$9.35
GF Value C$8.63
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Knight Therapeutics Beneish M-Score?

Knight Therapeutics TSX:GUD +1.30% 73 Beneish M-Score is -2.70 as of Jun. 25, 2026. GuruFocus rates TSX:GUD with a GF Score™ of 73/100 and a GF Value™ of C$8.63 (Fairly Valued). The stock has 6 warning signs investors should review. Among 911 Drug Manufacturers companies, Knight Therapeutics ranks better than 68.28% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.7 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Knight Therapeutics's Beneish M-Score or its related term are showing as below:

TSX:GUD' s Beneish M-Score Range Over the Past 10 Years
Min: -2.97   Med: -2.37   Max: 8.08
Current: -2.7

During the past 13 years, the highest Beneish M-Score of Knight Therapeutics was 8.08. The lowest was -2.97. And the median was -2.37.


Knight Therapeutics Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Knight Therapeutics's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Knight Therapeutics Beneish M-Score Chart

Knight Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.67 -2.42 -2.62 -2.45 -2.72

Knight Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.30 -2.59 -2.49 -2.72 -2.70

TSX:GUD vs ZTS: Beneish M-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Knight Therapeutics's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Knight Therapeutics Beneish M-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Knight Therapeutics's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Knight Therapeutics's Beneish M-Score falls into.


TSX:GUD
73GF Score
Knight Therapeutics Inc TSX:GUD
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Knight Therapeutics Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Knight Therapeutics for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.9111+0.528 * 0.9786+0.404 * 1.0651+0.892 * 1.3693+0.115 * 1.0671
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9452+4.679 * -0.092479-0.327 * 1.2183
=-2.70

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was C$156.6 Mil.
Revenue was 148.439 + 133.106 + 121.548 + 107.358 = C$510.5 Mil.
Gross Profit was 69.109 + 64.723 + 55.81 + 44.831 = C$234.5 Mil.
Total Current Assets was C$447.0 Mil.
Total Assets was C$1,086.6 Mil.
Property, Plant and Equipment(Net PPE) was C$30.4 Mil.
Depreciation, Depletion and Amortization(DDA) was C$61.2 Mil.
Selling, General, & Admin. Expense(SGA) was C$132.4 Mil.
Total Current Liabilities was C$192.4 Mil.
Long-Term Debt & Capital Lease Obligation was C$48.2 Mil.
Net Income was 13.169 + 8.854 + -3.791 + -12.622 = C$5.6 Mil.
Non Operating Income was 5.293 + 7.719 + -1.302 + -11.593 = C$0.1 Mil.
Cash Flow from Operations was 40.694 + 34.872 + 10.163 + 20.252 = C$106.0 Mil.
Total Receivables was C$125.5 Mil.
Revenue was 88.076 + 96.864 + 92.263 + 95.573 = C$372.8 Mil.
Gross Profit was 34.866 + 40.352 + 45.017 + 47.337 = C$167.6 Mil.
Total Current Assets was C$454.0 Mil.
Total Assets was C$1,003.0 Mil.
Property, Plant and Equipment(Net PPE) was C$21.0 Mil.
Depreciation, Depletion and Amortization(DDA) was C$52.1 Mil.
Selling, General, & Admin. Expense(SGA) was C$102.3 Mil.
Total Current Liabilities was C$152.6 Mil.
Long-Term Debt & Capital Lease Obligation was C$29.7 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(156.612 / 510.451) / (125.526 / 372.776)
=0.306811 / 0.336733
=0.9111

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(167.572 / 372.776) / (234.473 / 510.451)
=0.449525 / 0.459345
=0.9786

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (446.951 + 30.371) / 1086.6) / (1 - (454.006 + 20.967) / 1003.042)
=0.56072 / 0.526467
=1.0651

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=510.451 / 372.776
=1.3693

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(52.112 / (52.112 + 20.967)) / (61.177 / (61.177 + 30.371))
=0.713091 / 0.668251
=1.0671

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(132.414 / 510.451) / (102.305 / 372.776)
=0.259406 / 0.274441
=0.9452

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((48.166 + 192.449) / 1086.6) / ((29.707 + 152.612) / 1003.042)
=0.221438 / 0.181766
=1.2183

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(5.61 - 0.117 - 105.981) / 1086.6
=-0.092479

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Knight Therapeutics has a M-score of -2.70 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.70 mean?
Knight Therapeutics (TSX:GUD) has a Beneish M-Score of -2.70 as of Jun. 25, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Knight Therapeutics and its competitors. According to the industry distribution chart, Knight Therapeutics ranks #289 out of 911 companies in the Drug Manufacturers industry, placing it in the top 31.7%.
Is Knight Therapeutics' Beneish M-Score too high?
Knight Therapeutics' current Beneish M-Score is -2.70. Based on the distribution chart, Knight Therapeutics ranks #289 out of 911 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Knight Therapeutics has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Knight Therapeutics' Beneish M-Score compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Knight Therapeutics ranks #289 out of 911 companies for Beneish M-Score. This puts Knight Therapeutics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Drug Manufacturers company?
A good Beneish M-Score depends on the Drug Manufacturers industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Knight Therapeutics and its competitors. Knight Therapeutics's current Beneish M-Score is -2.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Knight Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Knight Therapeutics (TSX:GUD) is currently considered Fairly Valued. The stock's GF Value™ is C$8.63, compared to a current price of C$9.35 — trading 8.3% above its estimated fair value. The current Beneish M-Score is -2.70. Knight Therapeutics' overall GF Score™ is 73/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Knight Therapeutics (TSX:GUD), the current Beneish M-Score is -2.70 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Knight Therapeutics (TSX:GUD) Overvalued in 2026?

Based on GuruFocus' analysis, Knight Therapeutics stock appears to be overvalued. The current stock price of C$9.35 is trading 8.3% above its estimated GF Value™ of C$8.63. GuruFocus considers Knight Therapeutics to be Fairly Valued.

Key valuation signals for TSX:GUD:

  • Beneish M-Score: -2.70
  • GF Value™: C$8.63 vs. price of C$9.35 (8.3% above fair value)
  • GF Score™: 73/100 with 6 warning signs

No single metric tells the full story. See the TSX:GUD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Knight Therapeutics Business Description

Other Exchanges KHTRF:USA
Address 100 Alexis Nihon Boulevard, Suite 600, Saint-Laurent, QC, CAN, H4M 2P2
Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and commercializing pharmaceuticalproducts. and distributing pharmaceutical products, consumer health products, and medical devices in Canada, Latin America and select international markets. The company finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights. Geographically, the company generates revenue from Brazil, Canada, Colombia, Argentina, Mexico, Rest of LATAM, and Others, with the majority revenue generated from the Brazil region.
73GF Score

Get the complete analysis for TSX:GUD

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$9.35
Price
C$8.63
GF Value